Abstract YO40
Case summary
Introduction: Giant cell tumor (GCT) of bone are benign but locally aggressive primary bone tumors.They occur predominantly in long bones of adolescents and young adults typically in the epiphysis. Malignant giant cell tumors of bone (MGCTB) are rare, occurring in less than 1% of GCT of bone. Primary malignant GCT (PMGCT) is a high-grade sarcoma that arises side by side with benign GCTs. Secondary malignant GCT (SMGCT) is a high-grade sarcoma that occurs at the site where a GCTwas previously treated either by radiotherapy (radiation-induced form) or surgery (evolutionary form).
Case Description: A 30 year old female presented with progressive swelling and pain around the left knee for six months without any significant preceding history. X- Ray showed an expansile lytic lesion involving epiphysis of tibia and features suggestive of GCT. She underwent tumor resection and custom made prosthesis replacement. Post op histopathology showedGCT.Six months later the pain and swelling recurred. She was re evaluated with CT left leg which showed recurrent GCT 20x20 cm with soft tissue extension.Biopsy showed malignancy with GCT.Whole body FDG-PET CT was suggestive of tumor recurrence in left proximal tibia with associated soft tissue mass with inguinal nodal and pulmonary metastasis. She received palliative RT 30Gy in 10 fractions.Due to local progression she underwent palliative above knee amputation. Post op histopathology was suggestive of giant cell rich sarcoma.She received 3 cycles of chemotherapy with cisplatin and adriamycin. She expired after 3rd cycle of chemotherapy.
Discussion:PMGCT typically is difficult to distinguish from giant cell tumor of bone, as clinical and radiographic presentation of PMGCT can mimic that of a benign lesion. Malignancies in GCTs are extremely rare events. Since these are aggressive tumors with poor prognosis, it is important that they be recognized at an early stage so that they can be treated adequately by aggressive surgery and chemotherapy.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
87P - Negative to positive lymph node ratio-prognostic marker of survival in node positive rectal cancer
Presenter: Pavan Jonnada
Session: Poster display session
Resources:
Abstract
88P - The Sidra LUMC advanced colon cancer NGS cohort
Presenter: Wouter Hendrickx
Session: Poster display session
Resources:
Abstract
89P - A phase II trial of adjuvant chemoradiotherapy for patients with high-risk rectal submucosal invasive cancer after local resection
Presenter: Masaaki Noguchi
Session: Poster display session
Resources:
Abstract
90P - High MICB expression confers prognostic benefit in colorectal cancer
Presenter: Shanchao Yu
Session: Poster display session
Resources:
Abstract
91P - Adjuvant therapy for high-risk stage II or stage III colon adenocarcinoma: A propensity score-matched, nationwide, population-based cohort study
Presenter: Chien-Hsin Chen
Session: Poster display session
Resources:
Abstract
92P - Prospective randomized controlled study comparing primary surgery versus neoadjuvant chemotherapy followed by surgery in gastric carcinoma
Presenter: Vipin Goel
Session: Poster display session
Resources:
Abstract
93P - Biomarker selection of liver metastatic colorectal patients for anti-EGFR monoclonal antibodies: A machine learning analysis
Presenter: Yijiao Chen
Session: Poster display session
Resources:
Abstract
94P - NORTH/HGCSG1003: North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: Final analysis
Presenter: Michio Nakamura
Session: Poster display session
Resources:
Abstract
95P - Anatomical resections improve relapse-free survival in patients with KRAS/NRAS/BRAF- mutated colorectal liver metastases
Presenter: Ye Wei
Session: Poster display session
Resources:
Abstract
96P - Incidence, characteristics and prognosis in colorectal cancer with CNS metastases
Presenter: Nicola Taylor
Session: Poster display session
Resources:
Abstract